

DAFTAR PUSTAKA

- Aggarwal V, Tuli H, Varol A, Thakral F, Yerer M, Sak K, Varol M, Jain A, Khan M, & Sethi G, (2019). Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. *Biomeleculs* 9 (735): 1-26.
- American Cancer Society, (2019). Key Statistics for Non-Hodgkin Lymphoma. [Online] Tersedia dari: <https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/key-statistics.html>
- American Diabetes Association, (2019). Standarts of Medical Care in Diabetes. [Online] Tersedia dari: https://care.diabetesjournals.org/content/diacare/suppl/2018/12/17/42.Suppl%201.DC1/DC_42_S1_2019_UPDATED.pdf
- Arunachalam S, Pichiah T, & Achiraman S, (2012). Doxorubicin Treatment Inhibits PPAR γ and May Induce Lipotoxicity by Mimicking a Type 2 Diabetes-like Condition in Rodent Models. *FEBS Letters* 587 (2013) 105-110.
- Ashariati A, (2015). Kemoterapi. Dalam: *Buku Ajar Ilmu Penyakit Dalam*. Eds: Tjokroprawiro A, Setiawan PB, Effendi C, Santoso D, Soegiarto G. Edisi ke-2. Surabaya: Airlangga University Press. Hal. 433-436.
- Cancer Statistics Digest, (2019). Incidence rates of malignant lymphoma in the world from the Cancer Incidence in Five Continents XI. *Japanese Journal of Clinical Oncology*, 2019, 1–2.
- Brady VJ, Grimes A, Amstrong T, & Wood GL, (2014). Management of Steroid-Induced Hyperglycemia in Hospitalized Patients with Cancer: A Review. *Oncology Nursing Forum* Volume 41 Number 6, E355-E365.
- Brady V, Thosani S, Zhou S, Bassett R, Busaidy NL, & Lavis V, (2014). Safe and Effective Dosing of Basal-Bolus Insulin in Patients Receiving High-Dose Steroids for Hyper-Cyclophosphamide, Doxorobucin, Vincristine, and Dexamethasone Chemotherapy. *Diabetes Technology & Therapeutics* Volume 16 Number 12: 874-879.
- Buttgereit F, Silva JAP, Boers M, Burmester GR, Cutolo M, Jacobs J, Kirwan J, Kohler L, Riel PV, Viscer T, & Bijlsma JWJ, (2002). Standardises Nomenclature for Glucocorticoid Dossages and Glucocorticoid Treatment Regimens: Current Questions and Tentative Answers in Rheumatology. *Ann Rheum Dis* 2002 (61): 718-722.
- Cai Q, Luo X, Liang Y, Rao H, Fang X, Jiang W, Lin T, & Huang H, (2013). Fasting Blood Glucose is a Novel Prognostic Indicator for Extranodal Natural Killer/ T-cell Lymphoma, Nasal Type. *British Journal of Cancer* 2013 (108): 380-386.

- Dahlan MS, (2018). Statistik untuk Kedokteran dan Kesehatan. Edisi ke-6 Seri 1. Jakarta: Epidemiologi Indonesia.
- Duan W, Shen X, Lei J, Xu Q, Yu Y, Li R, Wu E, & Ma Q, (2014). Hyperglycemia, a Neglected Factor during Cancer Progression. *BioMed Research International Volume 2014, 1-10*.
- Farinde, (2019). Corticosteroid Dose Equivalents. [Online] Tersedia dari: <https://emedicine.medscape.com/article/2172042-overview>
- Flory J & Farooki A, (2016). Diabetes Management in Cancer Patients. [Online] Tersedia dari: <https://www.cancernetwork.com/oncology-journal/diabetes-management-cancer-patients>
- Gerards, (2018). Glucocorticoid-Induced Hyperglycemia. Amsterdam: University of Amsterdam.
- Gonzalez JGG, Zavala LGM, Gutierrez RR, Almaguer DG, Gonzalez FJL, Perez HET, Saldivar GG, & Perez JZV, (2013). Hyperglycemia Related to High-Dose Glucocorticoid Use in Noncritically Ill Patients. *Diabetology & Metabolic Syndrome 2013, 5:18, 1-7*.
- Gupta & Bhatia, (2008). Corticosteroid Physiology and Principles of Therapy. *Indian Journal of Pediatrics 75 (2008): 1039-1044*.
- Harris D, Barts A, Connors J, Dahl M, Elliott T, Kong J, Keane T, Thompson D, Stafford S, Ur E, & Sirrs S, (2013). Glucocorticoid-Induced Hyperglycemia is Prevalent and Unpredictable for Patients Undergoing Cancer Therapy: An Observational Cohort Study. *Current Oncology Volume 20 Number 6, pp.e532-538*.
- Heart E, Karandrea S, Liang X, Balke M, Beringer P, Bobczynski E, Burgos D, Richardson T, & Gray J, (2016). Mechanism of Doxorubicin Toxicity in Pancreatic β -Cells. *Toxicological Sciences 152 (2): 395-405*.
- Internasional Diabetes Federation, (2017). IDF Diabetes Atlas 8th Edition 2017.
- Jeong Y, Han HS, Lee HD, Yang J, Jeong J, Choi MK, Kwon J, Jeon HJ, Oh TK, Lee KH, & Kim SK, (2016). A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients. *Cancer Res Treat 2016, 48(8): 1429-1437*.
- Joint British Diabetes Societies, (2014). Management of Hyperglycemia and Steroid (Glucocorticoid) Therapy for Inpatient Care.
- Junior E, Yamashita A, Pimentel G, Sousa L, Santos R, Goncalves C, Streck E, Lira F, & Neto J, (2016). Doxorubicin Caused Svere Hyperglycemia and Insulin Resistence, Mediated by Inhibition in AMPk Signaling in Skeletal Muscle. *Journal of Cachexia, Sarcopenia, and Muscle 2016 (7): 615-625*.
- Kaneto H, Katakami N, Matsuhisa M, & Matsuoka T, (2009). Role of Reactive Oxygen Species in the Progression of Type 2 Diabetes and Atherosclerosis. *Mediators of Inflammation 2010 (11): 1-11*.
- Katzung BG, Hall MK, & Trevor AJ, (2019). Pharmacology Examination & Board Review. Mc Graw Hill, Lange.

- Kementerian Kesehatan Republik Indonesia, (2014). Situasi dan Analisis Diabetes. Jakarta: Kementerian Kesehatan RI.
- Kementerian Kesehatan Republik Indonesia, (2015a). Data dan Kondisi Penyakit Limfoma di Indonesia. Jakarta: Kementerian Kesehatan RI.
- Kementerian Kesehatan Republik Indonesia, (2015b). Panduan Penatalaksanaan Limfoma Non-Hodgkin. Jakarta: Kementerian Kesehatan RI.
- Lamar ZS, (2016). The Role of Glucocorticoids in the Treatment of Non-Hodgkin Lymphoma. *Annals of Hematology and Oncology Volume 3 Issue 7, 1-5*.
- Lamar ZS, Dothard A, Kennedy L, Isom S, Robinson M, Vaidya R, Hurd D, McClain D, & Lesser G, (2018). Hyperglycemia During First-Line R-CHOP or Dose Adjusted R-EPOCH Chemotherapy for Non-Hodgkin Lymphoma is Prevalent and Associated with Chemotherapy Alteration – A Retrospective Study. *Leuk Lymphoma 59(8): 1871-1877*.
- Lee AY, Kurita N, Yokoyama Y, Seki M, Hasegawa Y, Okoshi Y, & Chiba S, (2013). Glucocorticoid-Induced Diabetes Mellitus in Patients with Lymphoma Treated with CHOP Chemotherapy. *Support Care Cancer: 1-6*.
- Lightfoot T, Skibola C, Smith A, Forrest M, Adamson P, Morgan G, Bracci P, Roman E, Smith M, & Holly E, (2006). Polymorphisms in the Oxidative Stress Genes, Superoxide Dismutase, Glutathione Peroxidase and Catalase and Risk of Non-Hodgkin's Lymphoma. *Haematologica 2006 91 (9): 1222-1227*.
- Mengko SK & Surarso B, (2009). Patogenesis Limfoma Non-Hodgkin Ekstra Nodal Kepala dan Leher. *Jurnal THT-KL.Vol.2,No.1, Januari – April 2009, hlm 32 – 47*.
- Mitri J, Castillo J, & Pittas A, (2008). Non-Hodgkin Lymphoma in Patients with Diabetes Mellitus: A Meta-Analysis. *Diabetes Care. 2008 Dec; 31(12): 2391-2397*.
- National Cancer Institute, (2017). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. [Online] Tersedia dari: <https://www.meddra.org/>
- National Comprehensive Cancer Network, (2019). B-Cell Lymphomas. [Online] Tersedia dari: <https://www.NCCN.org>
- National Comprehensive Cancer Network, (2020). Antiemesis. [Online] Tersedia dari: <https://www.NCCN.org>
- NHS, (2016). Guideline for the Management of Chemotherapy-induced Nausea and Vomiting. [Online] Tersedia dari: <https://www.england.nhs.uk/mids-east/wp-content/uploads/sites/7/2018/04/antiemetic-policy-2016.pdf>
- Nieman L, (2019). Pharmacologic Use of Glucocorticoids. [Online] Tersedia dari: [https:// www.UptoDate.com](https://www.UptoDate.com)
- Oyer DS, Shah A, & Bettenhausen S, (2006). How to Manage Steroid Diabetes in the Patient with Cancer. *Supportive Oncology Volume 4 Number 9: 479-483*.

- Paramartha IK & Rena RA, (2017). Karakteristik Pasien Limfoma Maligna di RSUP Sanglah Tahun 2015. *E-Jurnal Medika* 6(2): 1-9.
- Perkumpulan Endokrinologi Indonesia, (2019a). Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia. Jakarta: PB PERKENI.
- Perkumpulan Endokrinologi Indonesia, (2019b). Pedoman Pengelolaan Dislipidemia di Indonesia. Jakarta: PB PERKENI.
- Pufall, (2015). Glucocorticoids and Cancer. *Adv Exp Med Biol.* 2015; 872: 315–333.
- Raalte DHV & Diamant M, (2014). Steroid diabetes: from mechanism to treatment?. *The Journal of Medicine Vol . 72 , no 2: 62-72.*
- Rinsho N, (2014). Abnormal p53-HDM2 Interaction in Hematological Malignancy. *Pubmed* 72(6): 1042-6.
- Rowbottom L, Stinson J, McDonald R, Emmenegger U, Cheng S, Lowe J, Giotis A, Cheon P, Chow R, Pasetka M, Thavarajah N, Pulenzas N, Chow E, & DeAngelis C, (2015). Retrospective Review of the Incidence of Monitoring Blood Glucose Levels in Patients Receiving Corticosteroid with Systemic Anti-Cancer Therapy. *Ann Palliat Med* 2015;4(2):70-77.
- Sastroasmoro S, & Ismael S, (2014). Dasar-dasar Metodologi Penelitian Klinis Edisi Ke-4. Jakarta: Sagung Seto. Hal. 348-382.
- Sedana MP, (2015). Limfoma Maligna. Dalam: *Buku Ajar Ilmu Penyakit Dalam*. Eds: Tjokroprawiro A, Setiawan PB, Effendi C, Santoso D, Soegiarto G. Edisi ke-2. Surabaya: Airlangga University Press. Hal. 400-408.
- Schultz H, Bjergaard UP, Jensen AK, Engelholm SA, & Kristensen PL, (2018). The Influence on Survival of Glucocorticoid Induced Diabetes in Cancer Patients with Metastatic Spinal Cord Compression. *Clinical and Translational Oncology* 11 (2018): 19-25.
- Schwartz S, Epstein S, Corkey B, Grant A, Gavin J, & Aguilar R, (2016). The Time is Right for a New Classification System for Diabetes: Rationale and Implications of the β -Cell-Centric Classification Schema. *Diabetes Care* 39 (2016): 179-186.
- Setyowati HG, Sadhana U, Kusuma MD, & Puspasari D, (2017). Ekspresi *Latent Membran Protein-1 (LMP-1) Epstein Barr Virus (EBV)* pada Limfoma Maligna. *Medical Faculty of Diponegoro University Voulme 2, Nomor 3: 185-190.*
- Sharma PK, Misra AK, Singh V, Gupta A, Saroha S, & Singh S, (2016). Cyclophosphamide and Epirubicin-induced Diabetes Mellitus in Breast Cancer: A Rare Occurrence. *Journal of Pharmacology and Pharmacotherapeutics Volume 7 Issue 3: 146-148.*
- Srokowski TP, Fang S, Hortobagyi GN, & Giordano SH, (2009). Impact of Diabetes Mellitus on Complications and Outcomes of Adjuvant Chemotherapy in Older Patients with Breast Cancer. *Journal of Clinical Oncology Volume 27 Number 13, 2170-2176.*

- Strycharz J, Drzewoski J, Szemraj J, & Sliwiska A, (2014). Is p53 Involved in Tissue-Specific Insulin Resistance Formation?. *Oxidative Medicine and Cellular Longevity Volume 2017, Article ID 9270549, 23 pages.*
- Suh S & Park MK, (2017). Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem. *Endocrinology and Metabolism 2017;32:180-189.*
- Supriya R, Tam BT, Pei XM, Lai CW, Chan LW, Yung BY, & Siu PM, (2016). Doxorubicin Induces Inflammatory Modulation and Metabolic Dysregulation in Diabetic Skeletal Muscle. *Frontiers in Physiology 7(323): 1-13.*
- Teppo H, Soini Y, & Karihtala P, (2017). Reactive Oxygen Species-Mediated Mechanism of Action of Targeted Cancer Therapy. *Oxidative Medicine and Cellular Longevity 2017: 1-12.*
- Volpe C, Delfino P, Anjos P, & Machado J, (2018). Cellular Death, Reactive Oxygen Species (ROS), and Diabetic Complications. *Cell Death and Disease 2018 (9): 119-127.*
- Widowati W, (2008). Potensi Antioksidan sebagai Antidiabetes. *JKM 7 (2) 1-11.*
- World Health Organization, (2016). Diabetes, Fakta dan Angka.
- Yang J, Jia B, Qiao Y, Chen W, & Qi X, (2016). Variations of Blood Glucose in Cancer Patients during Chemotherapy. *Nigerian Journal of Clinical Practice, 704-708.*
- Yang J, Wang Y, Liu K, Yang W, & Zhang J, (2019). Risk Factors for Doxorubicin-Induced Serious Hyperglycemia-Related Adverse Drug Reactions. *Diabetes Ther: 1-9.*